Ultrafast Genome Sequencer 20 System Finds its Application in Ever-Increasing Fields of Life Science Research
News Mar 02, 2006
Roche Diagnostics has announced that the ultrafast Genome Sequencer 20 System finds its application in ever-increasing fields of life science research.
In a recent publication, K. Andries et al. reported on the antimycobacterial properties of the diarylquinolines (DARQs).
The lead compound, R207910, not only has several properties that may improve the treatment of tuberkulosis, but also appears to act at a new target, providing an antimycobacterial spectrum different from those of current drugs.
The researchers used the Genome Sequencer 20 technology for target identification. Andries et al. found the target and mechanism of action of R207910 different from those of other anti-TB agents.
Inhibition of ATP synthase function may lead to ATP depletion and imbalance in pH homeostasis, both contributing to decreased survival.
In comparing the ATP synthases sequences of different bacteria and of eukaryotic ATP synthase the researchers found a rationale for the specificity of the antibacterial spectrum, and - to a lesser extent - the safety profile of R207910.
A further finding was that the distinct target of R207910 indicates the lack of crossresistance with existing anti-TB drugs. The studies verified that R207910 is as effective against MDR strains as it is against fully antibiotic-susceptible strains.
The DARQ R207910 belongs to a new chemical class of antimycobacterial agents and has a MIC equal to or lower than that of reference compounds.
Its spectrum is unique in its specificity to mycobacteria, including typical species important in humans such as MAC, M. kansasii, and the fast growers M. fortuitum and M. abscessus.
According to Andries et al.’s paper, the clinical use of R207910 will be targeted to the treatment of TB and mycobacterial infections.
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.